RAD51 as an immunohistochemistry-based marker of poly(ADP-ribose) polymerase inhibitor resistance in ovarian cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Yoo-Na | - |
dc.contributor.author | Kim, Kyeongmin | - |
dc.contributor.author | Joung, Je-Gun | - |
dc.contributor.author | Kim, Sang Wun | - |
dc.contributor.author | Kim, Sunghoon | - |
dc.contributor.author | Lee, Jung-Yun | - |
dc.contributor.author | Park, Eunhyang | - |
dc.date.accessioned | 2024-06-11T08:30:57Z | - |
dc.date.available | 2024-06-11T08:30:57Z | - |
dc.date.issued | 2024-04 | - |
dc.identifier.issn | 2234-943X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/26295 | - |
dc.description.abstract | Objective Effective functional biomarkers that can be readily used in clinical practice to predict poly(ADP-ribose) polymerase inhibitor (PARPi) sensitivity are lacking. With the widespread adoption of PARPi maintenance therapy in ovarian cancer, particularly in patients with BRCA mutation or HR deficiencies, accurately identifying de novo or acquired resistance to PARPi has become critical in clinical practice. We investigated RAD51 immunohistochemistry (IHC) as a functional biomarker for predicting PARPi sensitivity in ovarian cancer.Methods Ovarian cancer patients who had received PARPi and had archival tissue samples prior to PARPi exposure ("pre-PARPi") and/or after progression on PARPi ("post-PARPi") were selected. RAD51 IHC expression was semi-quantitatively evaluated using the H-score in geminin (a G2/S phase marker)- and gamma H2AX (a DNA damage marker)-positive tissues. A RAD51 H-score of 20 was used as the cutoff value.Results In total, 72 samples from 56 patients were analyzed. The median RAD51 H-score was 20 (range: 0-90) overall, 10 (0-190) in pre-PARPi samples (n = 34), and 25 (1-170) in post-PARPi samples (n = 19). Among patients with BRCA mutations, RAD51-low patients had better progression-free survival (PFS) after PARPi treatment than RAD51-high patients (P = 0.029). No difference was found in PFS with respect to the genomic scar score (P = 0.930). Analysis of matched pre- and post-PARPi samples collected from 15 patients indicated an increase in the RAD51 H-score upon progression on PARPi, particularly among pre-PARPi low-RAD51-expressing patients.Conclusion RAD51 is a potential functional IHC biomarker of de novo and acquired PARPi resistance in BRCA-mutated ovarian cancer and can be used to fine-tune ovarian cancer treatment. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | FRONTIERS MEDIA SA | - |
dc.title | RAD51 as an immunohistochemistry-based marker of poly(ADP-ribose) polymerase inhibitor resistance in ovarian cancer | - |
dc.type | Article | - |
dc.publisher.location | 스위스 | - |
dc.identifier.doi | 10.3389/fonc.2024.1351778 | - |
dc.identifier.scopusid | 2-s2.0-85192980198 | - |
dc.identifier.wosid | 001215871600001 | - |
dc.identifier.bibliographicCitation | FRONTIERS IN ONCOLOGY, v.14 | - |
dc.citation.title | FRONTIERS IN ONCOLOGY | - |
dc.citation.volume | 14 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | HOMOLOGOUS RECOMBINATION DEFICIENCY | - |
dc.subject.keywordPlus | BRCA WILD-TYPE | - |
dc.subject.keywordPlus | PARP INHIBITOR | - |
dc.subject.keywordPlus | TUMOR | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | MUTATIONS | - |
dc.subject.keywordPlus | OLAPARIB | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | WOMEN | - |
dc.subject.keywordAuthor | ovarian cancer | - |
dc.subject.keywordAuthor | immunohistochemistry | - |
dc.subject.keywordAuthor | RAD51 | - |
dc.subject.keywordAuthor | PARP inhibitor | - |
dc.subject.keywordAuthor | resistance | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.